Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Renn, Jenn Huei ^a,b   Yang, Nan Ping ^a,c   Chou, Pesus ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b YULI VETERANS HOSPITAL   (Taiwan)

^c TAO YUAN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ESTRADIOL; MAGNESIUM; NEUROLEPTIC AGENT; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; PROLACTIN; TESTOSTERONE; THYROID HORMONE; THYROTROPIN; URIC ACID; CALCIUM; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; BONE MASS; CALCANEUS; CALCIUM BLOOD LEVEL; CROSS LINKING; DISEASE ASSOCIATION; ECHOGRAPHY; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; HYPERMAGNESEMIA; HYPERPROLACTINEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MENSTRUATION; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; SCHIZOPHRENIA; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; URIC ACID BLOOD LEVEL; ADULT; BLOOD; OSTEOPOROSIS; RISK FACTOR; STATISTICAL MODEL;

ADULT; ANTIPSYCHOTIC AGENTS; CALCANEUS; CALCIUM; COLLAGEN TYPE I; ESTRADIOL; FEMALE; HUMANS; LOGISTIC MODELS; MAGNESIUM; MALE; OSTEOCALCIN; OSTEOPOROSIS; PARATHYROID HORMONE; PEPTIDES; PHOSPHATES; PROLACTIN; RISK FACTORS; SCHIZOPHRENIA; TESTOSTERONE; THYROTROPIN; YOUNG ADULT;

EID: 77949294619     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-35     Document Type: Article

References (49)

1. Age and bone mass as predictors of fracture in a prospective study. SL Hui CW Slemenda CC Johnston Jr, J Clin Invest 1988 81 1804 1809 10.1172/JCI113523 3384952
2. NIH Consensus Statement. Osteoporosis prevention, diagnosis, and therapy. 2000 17 1 1 36
3. Consensus conference: Osteoporosis. JAMA 1984 252 799 802 10.1001/jama.252.6.799 6748181
4. The future of hip fractures in the United States. Numbers, costs, and potential effects of postmenopausal estrogen. SR Cummings SM Rubin D Black, Clin Orthop Relat Res 1990 163 166 2302881
5. The incidence of operationally defined schizophrenia in Camberwell, 1965-84. D Castle S Wessely G Der RM Murray, Br J Psychiatry 1991 159 790 794 10.1192/bjp.159.6.790 1790446
6. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. DA Regier WE Narrow DS Rae RW Manderscheid BZ Locke FK Goodwin, Arch Gen Psychiatry 1993 50 85 94 8427558
7. Testing the association between the incidence of schizophrenia and social capital in an urban area. JB Kirkbride J Boydell GB Ploubidis C Morgan P Dazzan K McKenzie RM Murray PB Jones, Psychol Med 2008 38 1083 1094 10.1017/S0033291707002085 17988420
8. Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP Study. P Fearon JB Kirkbride C Morgan P Dazzan K Morgan T Lloyd G Hutchinson J Tarrant WL Fung J Holloway, et al. Psychol Med 2006 36 1541 1550 10.1017/S0033291706008774 16938150
9. The incidence of schizophrenia in European immigrants to Canada. GN Smith J Boydell RM Murray S Flynn K McKay M Sherwood WG Honer, Schizophr Res 2006 87 205 211 10.1016/j.schres.2006.06.024 16905294
10. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. JB Kirkbride P Fearon C Morgan P Dazzan K Morgan J Tarrant T Lloyd J Holloway G Hutchinson JP Leff, et al. Arch Gen Psychiatry 2006 63 250 258 10.1001/archpsyc.63.3.250 16520429
11. The association of inequality with the incidence of schizophrenia - an ecological study. J Boydell J van Os K McKenzie RM Murray, Soc Psychiatry Psychiatr Epidemiol 2004 39 597 599 10.1007/s00127-004-0789-6 15300368
12. Incidence of schizophrenia in south-east London between 1965 and 1997. J Boydell J Van Os M Lambri D Castle J Allardyce RG McCreadie RM Murray, Br J Psychiatry 2003 182 45 49 10.1192/bjp.182.1.45 12509317
13. Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment. J Boydell J van Os K McKenzie J Allardyce R Goel RG McCreadie RM Murray, BMJ 2001 323 1336 1338 10.1136/bmj.323.7325.1336 11739218
14. Comparison of the incidence of schizophrenia in rural Dumfries and Galloway and urban Camberwell. J Allardyce J Boydell J Van Os G Morrison D Castle RM Murray RG McCreadie, Br J Psychiatry 2001 179 335 339 10.1192/bjp.179.4.335 11581114
15. Age-period-cohort analysis of the incidence of schizophrenia in Scotland. N Takei G Lewis PC Sham RM Murray, Psychol Med 1996 26 963 973 10.1017/S0033291700035297 8878329
16. The relationship of environmental temperature to the incidence and outcome of schizophrenia. S Gupta RM Murray, Br J Psychiatry 1992 160 788 792 10.1192/bjp.160.6.788 1617362
17. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. CP Carney L Jones RF Woolson, J Gen Intern Med 2006 21 1133 1137 10.1111/j.1525-1497.2006.00563.x 17026726
18. Medical illness in patients with schizophrenia. LS Goldman, J Clin Psychiatry 1999 60 Suppl 21 10 15 10548136
19. Physical illness and schizophrenia: a review of the literature. S Leucht T Burkard J Henderson M Maj N Sartorius, Acta Psychiatr Scand 2007 116 317 333 10.1111/j.1600-0447.2007.01095.x 17919153
20. Detection and management of comorbidity in patients with schizophrenia. AI Green CM Canuso MJ Brenner JD Wojcik, Psychiatr Clin North Am 2003 26 115 139 10.1016/S0193-953X(02)00014-X 12683263
21. Osteoporosis and schizophrenia: can we limit known risk factors? G Abraham RH Friedman C Verghese J de Leon, Biol Psychiatry 1995 38 131 132 10.1016/0006-3223(95)00062-L 7578648
22. Bone mass in schizophrenia and normal populations across different decades of life. JH Renn NP Yang CM Chueh CY Lin TH Lan P Chou, BMC Musculoskeletal Disorders 2009 10 1 10.1186/1471-2474-10-1 19118498
23. Studies upon Calcification in vitro. PG Shipley B Kramer J Howland, Biochem J 1926 20 379 387 16743669
24. Hypermagnesemia: a cause of abnormal metaphyses in the neonate. WA Cumming VJ Thomas, AJR Am J Roentgenol 1989 152 1071 1072 2705341
25. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. M Hummer J Huber, Curr Med Res Opin 2004 20 189 197 10.1185/030079903125002865 15006013
26. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. U Halbreich S Palter, Schizophr Bull 1996 22 447 454 8873295
27. DF Levinson FM Simpson, Antipsychotic drug side effects Washington, DC: American Psychiatric Association 1987
28. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. AM Meaney S Smith OD Howes M O'Brien RM Murray V O'Keane, Br J Psychiatry 2004 184 503 508 10.1192/bjp.184.6.503 15172944
29. Bone histomorphometric study of the ilium in psychiatric patients with longterm administration of anti-psychiatric drugs. K Kutsuma, Nippon Seikeigeka Gakkai Zasshi 1993 67 583 590 8409629
30. Bone mineral density and prolactin associations in patients with chronic schizophrenia. G Abraham U Halbreich RH Friedman RC Josiassen, Schizophr Res 2003 59 17 18 10.1016/S0920-9964(01)00321-8 12413637
31. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? V O'Keane AM Meaney, J Clin Psychopharmacol 2005 25 26 31 10.1097/01.jcp.0000150223.31007.e0 15643097
32. Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. D Coss L Yang CB Kuo X Xu RA Luben AM Walker, Am J Physiol Endocrinol Metab 2000 279 1216 1225 11093907
33. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. D Becker O Liver R Mester M Rapoport A Weizman M Weiss, J Clin Psychiatry 2003 64 761 766 12934975
34. Decreased bone mineral density in medicated psychiatric patients. U Halbreich N Rojansky S Palter M Hreshchyshyn J Kreeger Y Bakhai R Rosan, Psychosom Med 1995 57 485 491 8552740
35. Bone density in amenorrheic women with and without hyperprolactinemia. JA Schlechte B Sherman R Martin, J Clin Endocrinol Metab 1983 56 1120 1123 10.1210/jcem-56-6-1120 6404918
36. Osteoporosis in men with hyperprolactinemic hypogonadism. SL Greenspan RM Neer EC Ridgway A Klibanski, Ann Intern Med 1986 104 777 782 3706929
37. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. T Kishimoto K Watanabe N Shimada K Makita G Yagi H Kashima, J Clin Psychiatry 2008 69 385 391 10.4088/JCP.v69n0307 18278991
38. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. G Abraham WW Paing J Kaminski A Joseph E Kohegyi RC Josiassen, Am J Psychiatry 2003 160 1618 1620 10.1176/appi.ajp.160.9.1618 12944336
39. Schizophrenia and osteoporosis. M Lean G De Smedt, Int Clin Psychopharmacol 2004 19 31 35 10.1097/00004850-200401000-00006 15101568
40. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. U Naidoo DC Goff A Klibanski, Psychoneuroendocrinology 2003 28 Suppl 2 97 108 10.1016/S0306-4530(02)00129-4 12650684
41. Decreased bone density in hyperprolactinemic women. A Klibanski RM Neer IZ Beitins EC Ridgway NT Zervas JW McArthur, N Engl J Med 1980 303 1511 1514 7432421
42. Osteoporosis associated with neuroleptic treatment. A case report. J Kartaginer K Ataya A Mercado A Abbasi, J Reprod Med 1990 35 198 202 1968102
43. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. K Ataya A Mercado J Kartaginer A Abbasi KS Moghissi, Fertil Steril 1988 50 876 881 2904890
44. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. M Bilici H Cakirbay M Guler M Tosun M Ulgen U Tan, Int J Neurosci 2002 112 817 828 10.1080/00207450290025833 12424822
45. Management of hyperprolactinemia in patients receiving antipsychotics. KK Miller, CNS Spectr 2004 9 28 32 15303078
46. The effects of atypical antipsychotics on serum prolactin levels. M Hamner, Ann Clin Psychiatry 2002 14 163 173 12585566
47. Comment on Hyperprolactinaemia and antipsychotic therapy in schizophrenia. OD Howes S Smith KJ Aitchison, Curr Med Res Opin 2004 20 1649 10.1185/030079904X4941 15462698
48. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. MA Krieg R Barkmann S Gonnelli A Stewart DC Bauer L Del Rio Barquero JJ Kaufman R Lorenc PD Miller WP Olszynski, et al. J Clin Densitom 2008 11 163 187 10.1016/j.jocd.2007.12.011 18442758
49. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. U Halbreich, CNS Drugs 2007 21 641 657 10.2165/00023210-200721080-00003 17630817